Will Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology?

As the field of artificial intelligence and machine learning (AI/ML) for drug discovery is rapidly advancing, we address the question “What is the impact of recent AI/ML trends in the area of Clinical Pharmacology?” We address difficulties and AI/ML developments for target identification, their use in generative chemistry for small molecule drug discovery, and the potential role of AI/ML in clinical trial outcome evaluation. We briefly discuss current trends in the use of AI/ML in health care and the impact of AI/ML context of the daily practice of clinical pharmacologists.

[1]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[2]  Tudor I. Oprea,et al.  Model-Free Drug-Likeness from Fragments , 2010, J. Chem. Inf. Model..

[3]  Hiroshi Nagamochi,et al.  Comparison and Enumeration of Chemical Graphs , 2013, Computational and structural biotechnology journal.

[4]  Alán Aspuru-Guzik,et al.  Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models , 2018, Frontiers in Pharmacology.

[5]  Jianying Hu,et al.  Artificial Intelligence for Clinical Trial Design. , 2019, Trends in pharmacological sciences.

[6]  Alán Aspuru-Guzik,et al.  Deep learning enables rapid identification of potent DDR1 kinase inhibitors , 2019, Nature Biotechnology.

[7]  W Patrick Walters,et al.  Assessing the impact of generative AI on medicinal chemistry , 2020, Nature Biotechnology.

[8]  Rim Shayakhmetov,et al.  3D Molecular Representations Based on the Wave Transform for Convolutional Neural Networks. , 2018, Molecular pharmaceutics.

[9]  Yoshua Bengio,et al.  Generative Adversarial Nets , 2014, NIPS.

[10]  S. Namazi,et al.  A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness , 2016, Journal of research in pharmacy practice.

[11]  Parag Kulkarni.  Reverse Hypothesis Machine Learning - A Practitioner's Perspective , 2017, Intelligent Systems Reference Library.

[12]  J. Aerts,et al.  Predicting disease-causing variant combinations , 2019, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[14]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[15]  Marco Viceconti,et al.  In silico clinical trials: how computer simulation will transform the biomedical industry , 2016 .

[16]  Evgeny Putin,et al.  Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes , 2016, bioRxiv.

[17]  Jae-Hoon Kim,et al.  Causality modeling for directed disease network , 2016, Bioinform..

[18]  Dmitry Vetrov,et al.  Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery. , 2018, Molecular pharmaceutics.

[19]  Tudor I. Oprea,et al.  Understanding drug‐likeness , 2011 .

[20]  Kaitlyn M. Gayvert,et al.  A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials. , 2016, Cell chemical biology.

[21]  Charu C. Aggarwal,et al.  Co-author Relationship Prediction in Heterogeneous Bibliographic Networks , 2011, 2011 International Conference on Advances in Social Networks Analysis and Mining.

[22]  Evgeny Putin,et al.  Adversarial Threshold Neural Computer for Molecular de Novo Design. , 2018, Molecular pharmaceutics.

[23]  Andrey Kazennov,et al.  The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology , 2016, Oncotarget.

[24]  J. Aronson.  A manifesto for clinical pharmacology from principles to practice. , 2010, British journal of clinical pharmacology.

[25]  Anton Simeonov,et al.  Unexplored therapeutic opportunities in the human genome , 2018, Nature Reviews Drug Discovery.